Molecular alteration patterns predict tumor behavior in papillary thyroid carcinoma independent of tumor size: insights from an international multicenter retrospective study
Open Access
- 8 April 2025
- journal article
- research article
- Published by Springer Nature in Thyroid Research
- Vol. 18 (1) , 1-8
Abstract
Molecular testing is a well-established tool that assists in the management of thyroid nodules and allows classification in distinct molecular alteration patterns: BRAF-like, RAS-like and non-BRAF-non-RAS (NBNR). Yet classical TNM classification and ATA guidelines currently rely on tumor size for risk stratification. In this study, we compared tumor behavior according to molecular alteration patterns versus tumor size. Retrospective multicenter multinational study of thyroid nodules that underwent preoperative molecular profiling with ThyGenX/ThyGeNEXT or ThyroSeq V3 between 2015 and 2022. Clinical characteristics, including demographics, cytology results, tumor size, surgical pathology, and molecular alterations, were analyzed. The study included 718 patients who underwent surgery for papillary thyroid cancer, with a majority of 556 (77.4%) being female. The distribution of molecular alteration patterns was as follows: BRAF-like in 227 (31.6%), RAS-like in 171 (23.8%), NBNR in 59 (8.2%), BRAF/RAS overlap 8 (1.1%) and no detectable mutation in 224 (31.2%) cases. The median tumor size was 15 mm (IQR 10–24). Extrathyroidal extension (ETE) was observed in 6.2% of cases with gross ETE and 5.6% with minimal ETE. Notably, nodules with BRAF-like molecular alterations were more likely to exhibit ETE compared to those with RAS-like or NBNR alterations (P < 0.001). There was no significant correlation between ETE and median tumor size (P > 0.05). Molecular testing of thyroid nodules provides a more accurate prediction of tumor behavior compared to tumor size alone. These findings suggest that future staging systems could benefit from incorporating molecular alteration patterns into their algorithms. - Retrospective multinational study on molecular profiling in thyroid cancer. - Vast majority of patients had T1 and T2 tumors (less than 4cm). - Nodules with BRAF-like alterations were more commonly associated with extrathyroideal extension and nodal metastasis. - Tumor size alone was not a predictor of extrathyroideal extension and/or nodal metastasis. - Molecular profiling may be a better predictor of tumor behaviour than tumor size, at least in tumors less than 4cm.Keywords
This publication has 39 references indexed in Scilit:
- The value of ACR, European, Korean, and ATA ultrasound risk stratification systems combined with RAS mutations for detecting thyroid carcinoma in cytologically indeterminate and suspicious for malignancy thyroid nodulesHormones, 2024
- Application of the Milan system for reporting salivary gland cytopathology using cell blocksVirchows Archiv, 2022
- Overview of the 2022 WHO Classification of Thyroid NeoplasmsEndocrine Pathology, 2022
- Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine‐needle aspirationDiagnostic Cytopathology, 2019
- Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodulesCancer, 2018
- Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid CarcinomaJAMA Oncology, 2016
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- The prognostic value of primary tumor size in papillary and follicular thyroid carcinomaCancer, 2005
- Prospective multicenter study of thyroid carcinoma treatmentCancer, 1998
- A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group1979